Menlo Therapeutics announces publication of Phase 2 serlopitant trial data
Menlo Therapeutics announced the publication of the company's Phase 2 trial of serlopitant for the treatment of pruritus associated with prurigo nodularis, or PN, in the Journal of the American Academy of Dermatology, or JAAD. The previously presented trial results demonstrate that serlopitant reduced pruritus in patients with treatment-refractory PN and was well-tolerated. The study met its primary and multiple secondary efficacy endpoints of pruritus reduction in patients in the serlopitant treatment group compared with placebo. In this randomized, double-blind, placebo-controlled study, 128 patients with chronic, treatment-refractory PN for more than 6 weeks received serlopitant, 5 mg, or placebo orally once daily for 8 weeks. For the primary endpoint assessment, pruritus scores were measured using the average itch visual analog scale. Pruritus scores improved significantly more in patients treated with serlopitant than in patients treated with placebo.